Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids.

Journal of medicinal chemistry·2026
Same author

Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer.

ACS chemical biology·2026
Same author

TOF-probe-based mass cytometry reveals individual protease activity as an important driver of immune cell differentiation and function.

Cell reports·2026
Same author

Identification and Exploration of a Series of SARS-Cov‑2 M<sup>Pro</sup> Cyano-Based Inhibitors Revealing Ortho-Substitution Effects within the P3 Biphenyl Group.

ACS medicinal chemistry letters·2025
Same author

A Robust Fluorogenic Substrate for Chikungunya Virus Protease (nsP2) Activity.

bioRxiv : the preprint server for biology·2025
Same author

Engineering unnatural amino acids in peptide linkers enables cathepsin-selective antibody-drug conjugates for HER2-positive breast cancer.

Journal of controlled release : official journal of the Controlled Release Society·2025

Related Experiment Video

Updated: Jun 9, 2026

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

Emerging principles in protease-based drug discovery.

Marcin Drag1, Guy S Salvesen

  • 1Program in Apoptosis and Cell Death Research, Burnham Institute for Medical Research, La Jolla, California 92037, USA. marcin.drag@pwr.wroc.pl

Nature Reviews. Drug Discovery
|September 3, 2010
PubMed
Summary

Developing protease inhibitors for diseases is crucial. Targeting allosteric sites offers a promising strategy to overcome challenges in achieving drug selectivity for new protease targets.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

Related Experiment Videos

Last Updated: Jun 9, 2026

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

Area of Science:

  • Biochemistry and Pharmacology
  • Drug Discovery and Development

Background:

  • Proteases play critical roles in numerous cellular signaling pathways.
  • They are recognized as key drug targets for various diseases, including cardiovascular disorders, cancer, and infectious diseases caused by parasites and viruses.
  • Established protease inhibitors, like those for angiotensin-converting enzyme and HIV protease, have demonstrated significant therapeutic benefits.

Purpose of the Study:

  • To discuss the fundamental principles of protease-based drug discovery.
  • To highlight key lessons learned from past drug development efforts.
  • To explore emerging strategies, such as allosteric site targeting, for developing novel protease inhibitors.

Main Methods:

  • Review and synthesis of existing literature on protease inhibitors and drug discovery.
  • Analysis of challenges in achieving target selectivity, particularly at protease active sites.
  • Discussion of emerging therapeutic strategies, focusing on allosteric site targeting.

Main Results:

  • Drug development for new protease targets faces challenges, partly due to difficulties in achieving selectivity.
  • Targeting the active sites of proteases can be problematic for drug development.
  • Allosteric site targeting presents a viable alternative strategy for protease inhibitor development.

Conclusions:

  • Protease-based drug discovery requires careful consideration of target selectivity.
  • Emerging strategies, particularly targeting allosteric sites, offer new avenues to harness the therapeutic potential of proteases.
  • Further research into allosteric modulation could lead to more effective treatments for a range of diseases.